(NYSE: MRK) Merck & Co's forecast annual revenue growth rate of 3.99% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 6.49%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 12.61%.
Merck & Co's revenue in 2026 is $66,569,000,000.On average, 30 Wall Street analysts forecast MRK's revenue for 2026 to be $167,081,797,668,636, with the lowest MRK revenue forecast at $160,694,290,297,854, and the highest MRK revenue forecast at $174,591,868,134,708. On average, 30 Wall Street analysts forecast MRK's revenue for 2027 to be $174,234,128,247,198, with the lowest MRK revenue forecast at $163,765,918,987,164, and the highest MRK revenue forecast at $187,667,877,816,108.
In 2028, MRK is forecast to generate $185,484,430,916,478 in revenue, with the lowest revenue forecast at $166,830,146,161,560 and the highest revenue forecast at $207,891,283,732,794.